Most cited papers from Ipsen (United Kingdom)

Ipsen (United Kingdom)

What are the most cited papers from Ipsen (United Kingdom)?

The most cited paper from Ipsen (United Kingdom) is "Neuromyelitis optica spectrum disorders" (Saif Huda, Dan Whittam, Maneesh Bhojak et al., 2019), with 287 citations. Next come "A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke" (217) and "A Double-Blind Randomised Placebo-Controlled Evaluation of Three Doses of Botulinum Toxin Type A (Dysport®) in the Treatment of Spastic Equinovarus Deformity after Stroke" (207).

Published TypeFieldAccessCitations

Showing 50 of 61 papers. Every paper with more than 21 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Neuromyelitis optica spectrum disorders Saif Huda, Dan Whittam, Maneesh Bhojak et al. · Clinical Medicine Open access	Mar 2019	287
2	A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke A. M. O. Bakheit, Sean Joseph Pittock, A. P. Moore et al. · European Journal of Neurology	14 Nov 2001	217
3	A Double-Blind Randomised Placebo-Controlled Evaluation of Three Doses of Botulinum Toxin Type A (Dysport®) in the Treatment of Spastic Equinovarus Deformity after Stroke Sean Joseph Pittock, A. P. Moore, Orla M. Hardiman et al. · Cerebrovascular Diseases	2003	207
4	AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients Malgorzata Field, Andrew Splevins, Philippe Picaut et al. · Toxins Open access	13 Dec 2018	156
5	The Expanding Therapeutic Utility of Botulinum Neurotoxins Elena Fonfría, Jacquie Maignel, Stéphane Lezmi et al. · Toxins Open access	18 May 2018	122
6	ACCORD guideline for reporting consensus-based methods in biomedical research and clinical practice: a study protocol William T Gattrell, A. P. S. Hungin, Amy I Price et al. · Research Integrity and Peer Review Open access	7 Jun 2022	120
7	Impact of short stature on quality of life: A systematic literature review Philippe Ferdinand Backeljauw, Marco Cappa, Wieland Kieß et al. · Growth Hormone & IGF Research ReviewOpen access	Apr 2021	116
8	Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches Kjell Öberg, Oriol Casanovas, Justo Pastor Castano et al. · Clinical Cancer Research	5 Mar 2013	90
9	Efficacy and safety of a standardised 500 unit dose of Dysport ® (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study J�rg Wissel, Petr Kaňovský, Evžen Růžička et al. · Journal of Neurology	Dec 2001	88
10	Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allerens in asthmatic patients a preliminary study Philippe Guinot, Christian Brambilla, Jacques Duchier et al. · Prostaglandins	Nov 1987	73
11	Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle STEPHEN L. DODD, Joshua Taylor Selsby, Anthony M. M. Payne et al. · Toxicon	22 Jun 2005	62
12	Sumoylation: Implications for Neurodegenerative Diseases Dina B. Anderson, Camila A. Zanella, Jeremy Martin Henley et al. · Advances in experimental medicine and biology Book chapter	2017	61
13	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis Jocelyn Quistrebert et al. · Seminars in Arthritis and Rheumatism Open access	11 Oct 2018	60
14	Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study Enrique Grande et al. · The Lancet Oncology	12 Dec 2023	59
15	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study Zev A. Wainberg, Tanios Bekaii‐Saab, Patrick McKay Boland et al. · European Journal of Cancer Open access	3 May 2021	59
16	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium Signe Hässler et al. · PLoS Medicine Open access	30 Oct 2020	59
17	Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use Naveed Panjwani, Roderic O’Keeffe, Andy Pickett · The Botulinum J	2008	59
18	Dysport®: Pharmacological properties and factors that influence toxin action Andy Pickett · Toxicon	30 Mar 2009	59
19	Investigating the Structural Compaction of Biomolecules Upon Transition to the Gas-Phase Using ESI-TWIMS-MS Paul W. A. Devine, Henry C. Fisher, Antonio N. Calabrese et al. · Journal of the American Society for Mass Spectrometry Open access	8 May 2017	56
20	The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. Sarah Adler et al. · PubMed	Aug 2010	56
21	Open Pharma recommendations for plain language summaries of peer-reviewed medical journal publications Adeline Rosenberg, Slávka Baróniková, Linda M. Feighery et al. · Current Medical Research and Opinion Open access	12 Sep 2021	54
22	Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors Liang Tao, Lisheng Peng, Ronnie P.‐A. Berntsson et al. · Nature Communications Open access	26 Jun 2017	54
23	Pain in cervical dystonia: mechanisms, assessment and treatment Raymond L. Rosales, Lorraine Cuffe, Benjamin Regnault et al. · Expert Review of Neurotherapeutics Open access	27 Sep 2021	53
24	A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours Damian Wild, Henning Grønbæk, Shaunak Navalkissoor et al. · European Journal of Nuclear Medicine and Molecular Imaging Open access	18 Sep 2023	51
25	Existing guidance on reporting of consensus methodology: a systematic review to inform ACCORD guideline development Esther J van Zuuren, Patrícia Logullo, Amy I Price et al. · BMJ Open ReviewOpen access	Sep 2022	48
26	Long‐term efficacy and tolerability of 4‐monthly versus yearly botulinum toxin type A treatment for lower‐limb spasticity in children with cerebral palsy Petr Kaňovský, Martin Bareš, Stanislav Severa et al. · Developmental Medicine & Child Neurology	8 May 2009	48
27	Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase Jasgit C. Sachdev, Pamela N. Münster, Donald W. Northfelt et al. · Breast Cancer Research and Treatment Open access	17 Nov 2020	47
28	Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study Aristotelis Bamias et al. · The Lancet Oncology	12 Dec 2023	45
29	Separation of the components of type A botulinum neurotoxin complex by electrophoresis Sapna Sharma, Mohhammad Ramzan, Bal Ram Singh · Toxicon	4 Feb 2003	44
30	Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity Elena Fonfría, Mark A. Elliott, Matthew Beard et al. · Toxins Open access	4 Jul 2018	43
31	Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit Lukas P. Degen, Fuping Peng, Annette Collet et al. · Gastroenterology	Feb 2001	43
32	Development of a patient journey map for people living with cervical dystonia Monika Benson, Alberto Albanese, Kailash P. Bhatia et al. · Orphanet Journal of Rare Diseases Open access	21 Mar 2022	42
33	Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models Mark A. Elliott, Christine Favre‐Guilmard, Sai Man Liu et al. · Science Advances Open access	4 Jan 2019	42
34	Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis Delphine Bachelet et al. · PLoS ONE Open access	2 Nov 2016	41
35	Serious issues relating to the clinical use of unlicensed botulinum toxin products Andy Pickett, Martin Mewies · Journal of the American Academy of Dermatology	19 Jun 2009	41
36	Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review Jayne L. Chamberlain, Saif Huda, Daniel H. Whittam et al. · Journal of Neurology	3 Sep 2019	40
37	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results Jenny Link et al. · PLoS ONE Open access	7 Feb 2017	40
38	Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review Sreenivasa Rao Chandana, Laura M. Woods, Fiona Maxwell et al. · European Journal of Cancer ReviewOpen access	12 Dec 2023	38
39	The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic William T Gattrell, Aurélie Barraux, Sam Comley et al. · Pharmaceutical Medicine Open access	26 Feb 2022	38
40	Anthrax toxins regulate pain signaling and can deliver molecular cargoes into ANTXR2+ DRG sensory neurons Nicole J. Yang et al. · Nature Neuroscience Open access	20 Dec 2021	37
41	Tanakan Inhibits Platelet-Activating-Factor-Induced Platelet Aggregation in Healthy Male Volunteers Pierre‐Grégoire Guinot, Emer Caffrey, Rory Lambe et al. · Haemostasis	24 Apr 2009	36
42	Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications Andy Pickett, STEPHEN L. DODD, Berthold Rzany · Journal of Cosmetic and Laser Therapy	2008	36
43	A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer R. Charles Coombes, Fátima Cardoso, Nicolás Isambert et al. · Breast Cancer Research and Treatment	24 Jun 2013	35
44	Towards New Uses of Botulinum Toxin as a Novel Therapeutic Tool Andy Pickett, Karen Perrow · Toxins Open access	12 Jan 2011	34
45	EFSPI/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets – a primer for academic researchers Rebecca Sudlow, Janice Branson, Tim Friede et al. · BMC Medical Research Methodology Open access	Jul 2016	30
46	Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons Charles Joussain, Olivier Le Coz, Andrey Pichugin et al. · Toxins Open access	19 Feb 2019	29
47	A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo Sarah Donald, Mark A. Elliott, Bryony Gray et al. · Pharmacology Research & Perspectives Open access	22 Nov 2018	29
48	Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics Jonathan R. Davies, Sai Man Liu, K. Ravi Acharya · Toxins Open access	20 Oct 2018	29
49	N‐terminal or signal peptide sequence engineering prevents truncation of human monoclonal antibody light chains Suzanne J. Gibson, Nicholas J. Bond, Stephen B Milne et al. · Biotechnology and Bioengineering	28 Mar 2017	29
50	Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy Linxiang Yin, Geoffrey Masuyer, Sicai Zhang et al. · PLoS Biology Open access	17 Mar 2020	28

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.